NCT04213118View on ClinicalTrials.gov

Anlotinib Combined With TACE in Hepatocellular Carcinoma Patients at High Risk of Post Surgery Recurrence

PHASE2UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 23, 2020

Primary Completion Date

February 28, 2023

Study Completion Date

September 30, 2023

Conditions
Hepatocellular CarcinomaTACEAnlotinib
Interventions
DRUG

Anlotinib Hydrochloride

Anlotinib 12mg QD PO d1-14, 21 days per cycle.

PROCEDURE

TACE

TACE first, followed by anlotinib within day4（+/-1days）

Trial Locations (4)

710000

Tangdu Hospital of The Fourth Military Medical University, Xi'an

The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an

723000

Hanzhong Central Hospital, Hanzhong

730000

The First Hospital of Lanzhou University, Lanzhou

Sponsors
All Listed Sponsors
collaborator

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY

lead

First Affiliated Hospital Xi'an Jiaotong University

OTHER